瑞信:比亞迪(1211.HK)9月份銷量強勁 維持目標價320港元
瑞信發表研究報吿指,比亞迪(1211.HK)九月份銷量按年升90%及按月升17%至8.01萬部,增長主要受新能源汽車銷量按年增長2.58倍的強勁表現帶動。該行維持“優於大市”評級,H股目標價320港元。
瑞信指,其中插電式混合動力車(PHEV)9月銷量按年升4.28倍至3.37萬部,當中包括1.52萬部“秦”、1.03萬部“宋”、5822部“唐”及2453部“漢”。
瑞信還指,如比亞迪需達到其全年銷售目標70萬部,公司需於第四季售出24.7萬部,即每月平均約8.2萬部,與9月份的銷售表現相若。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.